The solar submillimeter-wave telescope (SST) is the only one of its kind dedicated to solar continuous observations. Two radiometers at 0.740 mm (405 GHz), and four at 1.415 mm (212 GHz) are placed in the Cassegrain focal plane of the 1.5-m dish at El Leoncito high altitude site, San Juan, Argentina. The aperture efficiencies are close to design predictions: 20% and 35% for 2 and 4 arcminutes beam sizes at 405 and 212 GHz, respectively. The positioner absolute pointing accuracy is 10 arcseconds. Spectral coverage is complemented by ground-based mid-infrared telescopes developed for high cadence observations in the continuum 10 micron band (30 THz), using small apertures and roomtemperature microbolometer cameras. Using the system, a new solar burst spectral component was discovered, exhibiting fluxes increasing for smaller wavelengths, separated from the well known microwave component. Rapid subsecond pulsations are common for all bursts. The pulsations onset times of appear to be connected to the launch times of CMEs. Active regions are brighter for shorter submillimeter-waves. Mid-IR bright regions are found closely associated with calcium plages and magnetic structures near the solar photosphere. Intense and rapid 10 micron brightening was detected on active centers in association with weak flares. These results raise challenging difficulties for interpretation

No abstract

IMPORTANCEThe monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or drug supplies for patients. OBJECTIVE To assess the virologic efficacy of casirivimab and imdevimab across different IV and SC doses compared with placebo. DESIGN, SETTING, AND PARTICIPANTS This phase 2, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study included outpatients with SARS-CoV-2 infection at 47 sites across the United States. Participants could be symptomatic or asymptomatic; symptomatic patients with risk factors for severe COVID-19 were excluded. Data were collected from December 15, 2020, to March 4, 2021. INTERVENTIONS Patients were randomized to a single IV dose (523 patients) of casirivimab and imdevimab at 300, 600, 1200, or 2400 mg or placebo; or a single SC dose (292 patients) of casirivimab and imdevimab at 600 or 1200 mg or placebo. MAIN OUTCOMES AND MEASURES The primary end point was the time-weighted average daily change from baseline (TWACB) in viral load from day 1 (baseline) through day 7 in patients seronegative for SARS-CoV-2 at baseline. RESULTS Among 815 randomized participants, 507 (282 randomized to IV treatment, 148 randomized to SC treatment, and 77 randomized to placebo) were seronegative at baseline and included in the primary efficacy analysis. Participants randomized to IV had a mean (SD) age of 34.6 (9.6) years (160 [44.6%] men; 14 [3.9%] Black; 121 [33.7%] Hispanic or Latino; 309 [86.1%] White); those randomized to SC had a mean age of 34.1 (10.0) years (102 [45.3%] men; 75 [34.7%] Hispanicor Latino; 6 [2.7%] Black; 190 [84.4%] White). All casirivimab and imdevimab treatments showed significant virologic reduction through day 7. Least-squares mean differences in TWACB viral load for casirivimab and imdevimab vs placebo ranged from -0.56 (95% CI; -0.89 to -0.24) log 10 copies/mL for the 1200-mg IV dose to -0.71 (95% CI, -1.05 to -0.38) log 10 copies/mL for the 2400-mg IV dose. There were no adverse safety signals or dose-related safety findings, grade 2 or greater infusionrelated or hypersensitivity reactions, grade 3 or greater injection-site reactions, or fatalities. Two serious adverse events not related to COVID-19 or the study drug were reported.

No abstract

No abstract